Home
EXEL
EXEL News

Latest Exelixis Inc. (EXEL) News on January 19, 2025

MT Newswires

a day ago

William O'Neil Initiates Exelixis at Buy

MT Newswires

2 days ago

Oppenheimer Adjusts Price Target on Exelixis to $41 From $38, Maintains Outperform Rating

BeiGene Stock Meets 80-Plus RS Rating Benchmark

Investor's Business Daily

3 days ago

BeiGene Stock Meets 80-Plus RS Rating Benchmark

MT Newswires

4 days ago

Truist Raises Price Target on Exelixis to $42 From $38, Maintains Buy Rating

Zacks Industry Outlook Highlights Incyte, BioMarin, Exelixis, Halozyme and Blueprint Medicines

Zacks

4 days ago

Zacks Industry Outlook Highlights Incyte, BioMarin, Exelixis, Halozyme and Blueprint Medicines

Argus Research

4 days ago

EXEL: Raising target price to $37.00

BridgeBio Pharma Stock Earns 87 RS Rating

Investor's Business Daily

4 days ago

BridgeBio Pharma Stock Earns 87 RS Rating

Why Exelixis (EXEL) is Poised to Beat Earnings Estimates Again

Zacks

4 days ago

Why Exelixis (EXEL) is Poised to Beat Earnings Estimates Again

5 Biotech Stocks Worth Adding to Your Portfolio in 2025

Zacks

4 days ago

5 Biotech Stocks Worth Adding to Your Portfolio in 2025

Exelixis Provides Preliminary 2024 Results and Outlook for 2025

Zacks

5 days ago

Exelixis Provides Preliminary 2024 Results and Outlook for 2025

Why Exelixis (EXEL) is a Top Value Stock for the Long-Term

Zacks

5 days ago

Why Exelixis (EXEL) is a Top Value Stock for the Long-Term

Exelixis Announces Preliminary Fiscal Year 2024 Financial Results, Provides 2025 Financial Guidance and Outlines Key Priorities and Milestones for 2025

Business Wire

6 days ago

Exelixis Announces Preliminary Fiscal Year 2024 Financial Results, Provides 2025 Financial Guidance and Outlines Key Priorities and Milestones for 2025

FDA Updates EXEL on Previously Scheduled ODAC Meeting for Cabozantinib

Zacks

8 days ago

FDA Updates EXEL on Previously Scheduled ODAC Meeting for Cabozantinib

MT Newswires

9 days ago

Exelixis Says FDA No Longer Discussing Application for Cabozantinib at Committee Meeting

Exelixis Provides Update on Oncologic Drugs Advisory Committee Meeting for Cabozantinib (CABOMETYX®) for the Treatment of Patients with Previously Treated Advanced Neuroendocrine Tumors

Business Wire

9 days ago

Exelixis Provides Update on Oncologic Drugs Advisory Committee Meeting for Cabozantinib (CABOMETYX®) for the Treatment of Patients with Previously Treated Advanced Neuroendocrine Tumors

Exelixis to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 13, 2025

Business Wire

12 days ago

Exelixis to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 13, 2025

Exelixis Stock Surges 50% in a Year: Is There Room for Further Growth?

Zacks

12 days ago

Exelixis Stock Surges 50% in a Year: Is There Room for Further Growth?

Exelixis price target raised to $38 from $34 at RBC Capital

TipRanks

19 days ago

Exelixis price target raised to $38 from $34 at RBC Capital

High Growth Tech Stocks to Watch in December 2024

Simply Wall St.

19 days ago

High Growth Tech Stocks to Watch in December 2024

MT Newswires

19 days ago

RBC Capital Adjusts Price Target on Exelixis to $38 From $34, Keeps Outperform Rating

Are You a Value Investor? This 1 Stock Could Be the Perfect Pick

Zacks

22 days ago

Are You a Value Investor? This 1 Stock Could Be the Perfect Pick

EXEL vs. INCY: Which Stock Should Value Investors Buy Now?

Zacks

24 days ago

EXEL vs. INCY: Which Stock Should Value Investors Buy Now?

Argus Research

a month ago

EXEL: Lowering target price to $35.00

Is Exelixis, Inc. (EXEL) the Best Performing Biotech Stock in 2024?

Insider Monkey

a month ago

Is Exelixis, Inc. (EXEL) the Best Performing Biotech Stock in 2024?

MT Newswires

a month ago

Exelixis Shares Decline After BMO Capital Downgrade

MT Newswires

a month ago

BMO Capital Downgrades Exelixis to Market Perform From Outperform, Raises Price Target to $40 From $36

The Zacks Analyst Blog Highlights Sarepta Therapeutics, ADMA Biologics, Exelixis and Alnylam

Zacks

a month ago

The Zacks Analyst Blog Highlights Sarepta Therapeutics, ADMA Biologics, Exelixis and Alnylam

4 Biotech Stocks Most Wall Street Analysts Are Bullish About

Zacks

a month ago

4 Biotech Stocks Most Wall Street Analysts Are Bullish About

Pfizer Stock Up 5% as 2025 Guidance Meets Investor Expectations

Zacks

a month ago

Pfizer Stock Up 5% as 2025 Guidance Meets Investor Expectations

Argus Research

a month ago

EXEL: Lowering target price to $36.00

MT Newswires

a month ago

Exelixis Risk/Reward Now 'More Balanced' With 2025 Catalysts Priced In, BofA Says

MT Newswires

a month ago

BofA Securities Downgrades Exelixis to Neutral, $39 Price Target

SpringWorks Therapeutics (SWTX) Up 14.5% Since Last Earnings Report: Can It Continue?

Zacks

a month ago

SpringWorks Therapeutics (SWTX) Up 14.5% Since Last Earnings Report: Can It Continue?

Why This 1 Value Stock Could Be a Great Addition to Your Portfolio

Zacks

a month ago

Why This 1 Value Stock Could Be a Great Addition to Your Portfolio

Argus Research

a month ago

EXEL: Rating decreased to a HOLD

Exelixis (EXEL) is an Incredible Growth Stock: 3 Reasons Why

Zacks

a month ago

Exelixis (EXEL) is an Incredible Growth Stock: 3 Reasons Why

EXEL or INCY: Which Is the Better Value Stock Right Now?

Zacks

a month ago

EXEL or INCY: Which Is the Better Value Stock Right Now?

AZN's Bladder Cancer sBLA for Imfinzi Gets FDA's Priority Tag

Zacks

a month ago

AZN's Bladder Cancer sBLA for Imfinzi Gets FDA's Priority Tag

2 Biotech Stocks to Buy Hand Over Fist in December

Motley Fool

a month ago

2 Biotech Stocks to Buy Hand Over Fist in December

Acadia (ACAD) Down 2.9% Since Last Earnings Report: Can It Rebound?

Zacks

a month ago

Acadia (ACAD) Down 2.9% Since Last Earnings Report: Can It Rebound?

Why Is Editas (EDIT) Down 36.5% Since Last Earnings Report?

Zacks

a month ago

Why Is Editas (EDIT) Down 36.5% Since Last Earnings Report?

Exelixis' (NASDAQ:EXEL) earnings growth rate lags the 29% CAGR delivered to shareholders

Simply Wall St.

a month ago

Exelixis' (NASDAQ:EXEL) earnings growth rate lags the 29% CAGR delivered to shareholders

Argus Research

2 months ago

EXEL: Lowering target price to $39.00

Argus Research

2 months ago

Daily – Vickers Top Buyers & Sellers for 12/03/2024

MT Newswires

2 months ago

Exelixis Insider Sold Shares Worth $2,200,200, According to a Recent SEC Filing

Techne (TECH) Up 2.2% Since Last Earnings Report: Can It Continue?

Zacks

2 months ago

Techne (TECH) Up 2.2% Since Last Earnings Report: Can It Continue?

Here's Why Exelixis (EXEL) is a Strong Momentum Stock

Zacks

2 months ago

Here's Why Exelixis (EXEL) is a Strong Momentum Stock

Exelixis (EXEL) Up 10.8% Since Last Earnings Report: Can It Continue?

Zacks

2 months ago

Exelixis (EXEL) Up 10.8% Since Last Earnings Report: Can It Continue?

Exelixis to Webcast Fireside Chats as Part of Investor Conferences in December

Business Wire

2 months ago

Exelixis to Webcast Fireside Chats as Part of Investor Conferences in December

ODAC to Discuss Exelixis' Application for Cabometyx Label Expansion

Zacks

2 months ago

ODAC to Discuss Exelixis' Application for Cabometyx Label Expansion

Zacks Investment Ideas feature highlights: InterDigital, Futu and Exelixis

Zacks

2 months ago

Zacks Investment Ideas feature highlights: InterDigital, Futu and Exelixis

Argus Research

2 months ago

EXEL: Raising target price to $40.00

MT Newswires

2 months ago

Exelixis Says US FDA Will Review Supplemental NDA for Prospective Treatment for Pancreatic Tumors in March

Exelixis Provides Regulatory Update Related to Supplemental New Drug Application for Cabozantinib (CABOMETYX®) for the Treatment of Patients with Previously Treated Advanced Neuroendocrine Tumors

Business Wire

2 months ago

Exelixis Provides Regulatory Update Related to Supplemental New Drug Application for Cabozantinib (CABOMETYX®) for the Treatment of Patients with Previously Treated Advanced Neuroendocrine Tumors

End of Year Rally: 3 Stocks to Watch (IDCC, FUTU, EXEL)

Zacks

2 months ago

End of Year Rally: 3 Stocks to Watch (IDCC, FUTU, EXEL)

Exelixis Stock Surges 25% in a Month: Time to Buy or Sell?

Zacks

2 months ago

Exelixis Stock Surges 25% in a Month: Time to Buy or Sell?

Exelixis (EXEL) is a Top-Ranked Value Stock: Should You Buy?

Zacks

2 months ago

Exelixis (EXEL) is a Top-Ranked Value Stock: Should You Buy?

3 Reasons Growth Investors Will Love Exelixis (EXEL)

Zacks

2 months ago

3 Reasons Growth Investors Will Love Exelixis (EXEL)

EXEL vs. CSLLY: Which Stock Is the Better Value Option?

Zacks

2 months ago

EXEL vs. CSLLY: Which Stock Is the Better Value Option?

Zacks.com featured highlights Amazon, Maplebear, Exelixis and Doximity

Zacks

2 months ago

Zacks.com featured highlights Amazon, Maplebear, Exelixis and Doximity

MT Newswires

2 months ago

Exelixis Insider Sold Shares Worth $1,428,822, According to a Recent SEC Filing

Argus Research

2 months ago

EXEL: Rating increased to a BUY

ADMA Biologics Inc (ADMA) Hits Fresh High: Is There Still Room to Run?

Zacks

2 months ago

ADMA Biologics Inc (ADMA) Hits Fresh High: Is There Still Room to Run?

Vericel Stock Sees RS Rating Shoot Higher

Investor's Business Daily

2 months ago

Vericel Stock Sees RS Rating Shoot Higher

What Makes Exelixis (EXEL) a Strong Momentum Stock: Buy Now?

Zacks

2 months ago

What Makes Exelixis (EXEL) a Strong Momentum Stock: Buy Now?

Here's Why Exelixis (EXEL) is a Strong Momentum Stock

Zacks

2 months ago

Here's Why Exelixis (EXEL) is a Strong Momentum Stock

MT Newswires

2 months ago

Exelixis Insider Sold Shares Worth $3,394,510, According to a Recent SEC Filing

Exelixis to Webcast Fireside Chats as Part of Investor Conferences in November

Business Wire

2 months ago

Exelixis to Webcast Fireside Chats as Part of Investor Conferences in November

Here's Why Exelixis (EXEL) is a Strong Value Stock

Zacks

2 months ago

Here's Why Exelixis (EXEL) is a Strong Value Stock

Argus Research

2 months ago

EXEL: Rating decreased to a HOLD

Here is Why Growth Investors Should Buy Exelixis (EXEL) Now

Zacks

2 months ago

Here is Why Growth Investors Should Buy Exelixis (EXEL) Now

Earnings Estimates Rising for Exelixis (EXEL): Will It Gain?

Zacks

2 months ago

Earnings Estimates Rising for Exelixis (EXEL): Will It Gain?

EXEL vs. CSLLY: Which Stock Should Value Investors Buy Now?

Zacks

2 months ago

EXEL vs. CSLLY: Which Stock Should Value Investors Buy Now?

Exelixis (EXEL) Reliance on International Sales: What Investors Need to Know

Zacks

2 months ago

Exelixis (EXEL) Reliance on International Sales: What Investors Need to Know

3 Magnificent Stocks Under $100 to Buy in November

Motley Fool

3 months ago

3 Magnificent Stocks Under $100 to Buy in November

Exelixis, Inc. Just Recorded A 18% EPS Beat: Here's What Analysts Are Forecasting Next

Simply Wall St.

3 months ago

Exelixis, Inc. Just Recorded A 18% EPS Beat: Here's What Analysts Are Forecasting Next

Morningstar Research

3 months ago

Analyst Report: Exelixis, Inc.

Exelixis price target raised to $36 from $33 at Piper Sandler

TipRanks

3 months ago

Exelixis price target raised to $36 from $33 at Piper Sandler

Morningstar Research

3 months ago

Analyst Report: Exelixis, Inc.

Thomson Reuters StreetEvents

3 months ago

Q3 2024 Exelixis Inc Earnings Call

Exelixis Beats on Q3 Earnings and Sales, Raises Annual Outlook

Zacks

3 months ago

Exelixis Beats on Q3 Earnings and Sales, Raises Annual Outlook

Exelixis Inc (EXEL) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic ...

GuruFocus.com

3 months ago

Exelixis Inc (EXEL) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic ...

Morningstar Research

3 months ago

Analyst Report: Exelixis, Inc.

Exelixis (EXEL) Q3 2024 Earnings Call Transcript

Motley Fool

3 months ago

Exelixis (EXEL) Q3 2024 Earnings Call Transcript

Exelixis (EXEL) Reports Q3 Earnings: What Key Metrics Have to Say

Zacks

3 months ago

Exelixis (EXEL) Reports Q3 Earnings: What Key Metrics Have to Say

MT Newswires

3 months ago

Exelixis Q3 Non-GAAP Earnings, Revenue Rise; Updates Guidance

Exelixis (EXEL) Q3 Earnings and Revenues Beat Estimates

Zacks

3 months ago

Exelixis (EXEL) Q3 Earnings and Revenues Beat Estimates

Associated Press Finance

3 months ago

Exelixis: Q3 Earnings Snapshot

Exelixis Announces Third Quarter 2024 Financial Results and Provides Corporate Update

Business Wire

3 months ago

Exelixis Announces Third Quarter 2024 Financial Results and Provides Corporate Update

Zacks Industry Outlook Highlights Exelixis, Blueprint Medicines, CRISPR, Amicus and Verona Pharma

Zacks

3 months ago

Zacks Industry Outlook Highlights Exelixis, Blueprint Medicines, CRISPR, Amicus and Verona Pharma

Why Exelixis (EXEL) is a Top Momentum Stock for the Long-Term

Zacks

3 months ago

Why Exelixis (EXEL) is a Top Momentum Stock for the Long-Term

5 Biotech Stocks Likely to Outperform as Industry Prospects Look Bright

Zacks

3 months ago

5 Biotech Stocks Likely to Outperform as Industry Prospects Look Bright

Here's Why Exelixis (EXEL) is a Great Momentum Stock to Buy

Zacks

3 months ago

Here's Why Exelixis (EXEL) is a Great Momentum Stock to Buy

Intra-Cellular Therapies (ITCI) Expected to Beat Earnings Estimates: Should You Buy?

Zacks

3 months ago

Intra-Cellular Therapies (ITCI) Expected to Beat Earnings Estimates: Should You Buy?

1 No-Brainer Stock to Buy With $40

Motley Fool

3 months ago

1 No-Brainer Stock to Buy With $40

Exelixis (EXEL) Earnings Expected to Grow: Should You Buy?

Zacks

3 months ago

Exelixis (EXEL) Earnings Expected to Grow: Should You Buy?

Why Exelixis (EXEL) is a Top Value Stock for the Long-Term

Zacks

3 months ago

Why Exelixis (EXEL) is a Top Value Stock for the Long-Term

EXEL or CSLLY: Which Is the Better Value Stock Right Now?

Zacks

3 months ago

EXEL or CSLLY: Which Is the Better Value Stock Right Now?

Biotech Stock Roundup: VNDA, JAZZ Up on Updates, NVAX Suffers Setback & More

Zacks

3 months ago

Biotech Stock Roundup: VNDA, JAZZ Up on Updates, NVAX Suffers Setback & More

Exelixis (EXEL) Soars 8.6%: Is Further Upside Left in the Stock?

Zacks

3 months ago

Exelixis (EXEL) Soars 8.6%: Is Further Upside Left in the Stock?

Share on Social Networks: